Skip to content

Discussion on the immune mode of "functional cure" in the treatment of chronic HBV infection with interferon

Discussion on the immune mode of "functional cure" in the treatment of chronic HBV infection with interferon

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500099299
Enrollment
Unknown
Registered
2025-03-21
Start date
2025-04-01
Completion date
Unknown
Last updated
2025-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic hepatitis B

Interventions

CHB patients who meet the criteria for ataxia:None

Sponsors

The First Affiliated Hospital of Naval Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Age >=18 years old, gender unlimited 2.The diagnosis of chronic hepatitis B is in accordance with the Chronic Hepatitis B Diagnosis and Treatment Guidelines (2022 edition). 3.HBsA<=1500Iu/ml 4. Agree to accept interferon therapy for "functional cure" 5. Agree to take an additional 5ml of peripheral blood on the basis of routine follow-up examination as needed for clinical research 6. With good compliance, can understand and sign informed consent

Exclusion criteria

Exclusion criteria: 1. Pregnancy or short-term pregnancy plan 2. A history of mental illness (a history of schizophrenia or severe depression), uncontrolled epilepsy 3.Decompensated cirrhosis 4.Uncontrolled autoimmune disease 5. Serious infections, retinal diseases, heart failure, chronic obstructive pulmonary disease and other underlying diseases 6. Acute and chronic infection with HCV, HDV, HEV and other hepatitis viruses 7.Combined with autoimmune diseases, HIV infection and other diseases that may affect the host immune status 8.Patients with previous interferon therapy and drug resistance 9. The researchers suggest that there may be patients with poor compliance

Design outcomes

Primary

MeasureTime frame
HBsAg;HBV DNA;

Secondary

MeasureTime frame
Alanine aminotransferase;

Countries

China

Contacts

Public ContactLiang Xuesong

The First Affiliated Hospital of Naval Medical University

liangxuesong2000@163.com+86 152 1660 1106

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026